KRAS mutations, which are found in 30% to 45% of all colorectal tumors, are excellent indicators of which patients will benefit from the addition of cetuximab, a drug which targets epidermal growth factor receptor (EGFR). If KRAS, a gene which is located upstream of EGFR, is mutated then patients are unlikely to respond to this drug as they will have no functional EGFR.

Testing for this particular mutation defines the predicted response to this drug. A recent study showed that combination therapy which included cetuximab reduced the risk for metastatic colorectal cancer growth or spread by 15%. KRAS mutation analysis is now therefore a standard of care necessary for all newly diagnosed CRCs.
Sample type and Volume required: 
Paraffin processed blocks or sections of tumour.

Tissue that has been decalcified in acid is not suitable.
Turnaround time: 
2 – 3 Weeks
Storage and transport: 
First class post within 4 days (temperature not to exceed 30°C during transport)
Cellular Pathology/ Histopathology at King's College Hospital
020 3299 3045 - General Queries
King's College Hospital
Bessemer Wing - 2nd Floor
Denmark Hill
London SE5 9RS
For clinical advice or interpretation of results, please contact the laboratory in the first instance.

Print as a PDF

Last updated: 07/08/2015